2021 Pipeline Insights Report on Beta – Lactamase Inhibitor – ResearchAndMarkets.com

DUBLIN–()–The “Beta – Lactamase Inhibitor – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Beta-Lactamase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Beta-Lactamase Inhibitor R&D. The therapies under development are focused on novel approaches for Beta-Lactamase Inhibitor.

Beta-Lactamase Inhibitor Report Insights

  • Beta-Lactamase Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Beta-Lactamase Inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

  • How many companies are developing Beta-Lactamase Inhibitor drugs?
  • How many Beta-Lactamase Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Beta-Lactamase Inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Beta-Lactamase Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Beta-Lactamase Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Entasis Therapeutics
  • VenatoRx Pharmaceuticals
  • Qpex Biopharma
  • Boston Pharmaceuticals
  • Merck Sharp and Dohme
  • Fedora Pharmaceuticals
  • Allecra Therapeutics
  • AbbVie
  • Arixa Pharmaceuticals
  • LegoChem Biosciences
  • Yuhan
  • Allergan
  • AstraZeneca
  • Antabio
  • Infex Therapeutics

Key Products

  • Durlobactam/sulbactam
  • Ceftibuten/VNRX 7145
  • QPX 7728
  • BOS 572
  • MK-7655A
  • Nacubactam
  • AAI-202
  • ARX 1796
  • LCB18 0055
  • YH-1177D
  • CEF-104
  • ANT2681

Key Topics Covered:


Executive Summary

Beta-Lactamase Inhibitor: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Beta-Lactamase Inhibitor – Analytical Perspective

In-depth Commercial Assessment

  • Beta-Lactamase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Beta-Lactamase Inhibitor Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Durlobactam/sulbactam: Entasis Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

CEF-104 : Allergan

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

QPX 7728: Qpex Biopharma

  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products

LCB18 0055: LegoChem Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

Beta-Lactamase Inhibitor Key Companies

Beta-Lactamase Inhibitor Key Products

Beta-Lactamase Inhibitor- Unmet Needs

Beta-Lactamase Inhibitor- Market Drivers and Barriers

Beta-Lactamase Inhibitor- Future Perspectives and Conclusion

Beta-Lactamase Inhibitor Analyst Views

Beta-Lactamase Inhibitor Key Companies


For more information about this clinical trials report visit https://www.researchandmarkets.com/r/jxwvcg

Source link